Heart Health Ingredients Market Size and Share
Heart Health Ingredients Market Analysis by Mordor Intelligence
The Heart Health Ingredients Market size is estimated at USD 9.41 billion in 2025, and is expected to reach USD 12.47 billion by 2030, exhibiting a CAGR of 5.80% during the forecast period (2025-2030). The market expansion is primarily attributed to demographic transitions, enhanced regulatory frameworks, and technological advancements in ingredient development and processing. According to the American Heart Association's comprehensive analysis, cardiovascular disease is expected to affect 61% of United States adults by 2050, with projected healthcare costs approaching USD 1.8 trillion. This substantial disease burden has intensified the focus on preventive nutrition solutions, particularly heart health ingredients, across the pharmaceutical and nutraceutical industries. The market growth is further propelled by the rising adoption of functional foods and dietary supplements, and the growing aging population worldwide. Additionally, the development of innovative ingredient formulations and increased research and development investments in heart-healthy compounds contribute to market expansion.
Key Report Takeaways
- By ingredient type, Omega-3 fatty acids held 36.14% of the heart health ingredients market share in 2024, while Coenzyme Q10 is projected to expand at a 6.98% CAGR to 2030.
- By source, plant-based inputs led with 56.55% revenue share in 2024; algae-derived alternatives are forecast to rise at a 7.15% CAGR through 2030.
- By form, powder formulations accounted for 61.12% of the heart health ingredients market size in 2024, whereas liquids are growing at a 7.56% CAGR to 2030.
- By application, dietary supplements captured 51.25% share of the heart health ingredients market size in 2024, and functional food and beverages are set to expand at a 6.87% CAGR by 2030.
- By geography, North America held 38.46% revenue in 2024; Asia-Pacific is advancing at a 7.21% CAGR through 2030.
Global Heart Health Ingredients Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of cardiovascular diseases globally | +1.2% | Global, with highest impact in Asia-Pacific and North America | Long term (≥ 4 years) |
| Increasing aging population and associated heart health concerns | +1.0% | Global, concentrated in developed markets | Long term (≥ 4 years) |
| Growing consumer awareness about preventive healthcare | +0.8% | North America and the European Union, expanding to Asia-Pacific | Medium term (2-4 years) |
| Integration of heart health ingredients in everyday food products | +0.7% | Global, led by North America and Europe | Medium term (2-4 years) |
| Government initiatives promoting heart health awareness | +0.5% | North America, the European Union, with emerging programs in Asia-Pacific | Short term (≤ 2 years) |
| Increased focus on personalized nutrition | +0.4% | North America and the European Union primarily | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Rising prevalence of cardiovascular diseases globally
Cardiovascular diseases (CVDs) represent a significant global health challenge, driving substantial growth in the heart health ingredients market. These diseases, which include coronary artery disease, stroke, and hypertension, are the primary cause of mortality worldwide. The prevalence of CVDs has increased due to sedentary lifestyles, unhealthy dietary habits, tobacco use, and rising rates of obesity and diabetes. As consumers become more aware of these health risks, they increasingly seek heart-healthy products, including functional foods, dietary supplements, and nutraceuticals. These products contain beneficial ingredients, including omega-3 fatty acids, phytosterols, fiber (beta-glucan), and antioxidants such as polyphenols, which help manage cholesterol levels, blood pressure, and overall cardiovascular health. The World Health Organization (WHO) data illustrates the magnitude of this health crisis, with cardiovascular diseases causing approximately 338,000 deaths in Germany, 222,700 in Italy, and 161,200 in Poland as of 2023 [1]Source: World Health Organization (WHO), "Deaths by sex and age group for a selected country or area and year", www.who.int. These statistics, even from countries with sophisticated healthcare systems, have prompted governments and health organizations worldwide to emphasize the importance of preventive healthcare measures.
Increasing aging population and associated heart health concerns
The aging global population drives the demand for heart health ingredients as older adults face higher cardiovascular risks and seek preventive healthcare solutions. Key factors influencing this trend include increased life expectancy, lower birth rates, and medical advancements. In 2023, Japan reported the highest proportion of people aged 65 years or above at 30% of its population, followed by Italy at 24%, according to World Bank data [2]Source: World Bank, "Population ages 65 and above (% of total population)", www.worldbank.org. The older demographic demonstrates higher supplement consumption and increased investment in preventive health measures, creating a strong market for evidence-based heart health ingredients. This age group also shows greater engagement with regular health screenings and preventive care protocols. Population forecasts indicate similar aging patterns across developed markets, with the 65+ age group expected to double by 2050 in many regions due to improved healthcare infrastructure and lower mortality rates.
Growing consumer awareness about preventive healthcare
The global heart health ingredients market is primarily driven by increasing consumer awareness of preventive healthcare. With cardiovascular diseases remaining the leading cause of death and rising healthcare costs, consumers are transitioning from reactive treatment approaches to preventive health strategies. This transformation stems from improved access to health information, enhanced nutritional education, and a broader societal emphasis on wellness and longevity. Government and public health organizations worldwide strengthen this preventive approach through policy initiatives and educational programs. The United States Food and Drug Administration (FDA) and international health ministries provide dietary guidelines recommending omega-3 fatty acids, whole grains, fruits, vegetables, and lean proteins, while approving specific health claims for heart health ingredients on product labels. Additionally, organizations like the CDC Foundation implement targeted campaigns, such as "Live to the Beat," which focuses on cardiovascular disease prevention among Black adults, and support the Million Hearts initiative to reduce heart attacks and strokes nationwide.
Integration of heart health ingredients in everyday food products
The incorporation of heart health ingredients into mainstream food and beverage products has expanded beyond traditional supplement formats, increasing market accessibility and regular consumption. Food manufacturers integrate these ingredients to comply with regulations and meet consumer health preferences. For instance, beta-glucan fortification in everyday foods offers opportunities to enhance dietary fiber intake. The fortification of plant-based beverages with omega-3 fatty acids addresses nutritional requirements while aligning with sustainability preferences, especially among vegetarian and vegan consumers. Regulatory frameworks support this integration through approved health claims for soluble fiber and plant sterols, providing market advantages for compliant products. Advancements in encapsulation and delivery systems improve ingredient stability and bioavailability across various food matrices, enabling broader product development opportunities.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Competition from conventional pharmaceutical products | -0.8% | Global, strongest in developed markets with established pharma presence | Long term (≥ 4 years) |
| Stringent regulatory requirements for ingredient approval and health claims | -0.6% | The European Union and North America primarily, expanding globally | Medium term (2-4 years) |
| Limited Consumer Awareness in Developing Regions | -0.4% | Asia-Pacific emerging markets, Latin America, Africa | Medium term (2-4 years) |
| Side Effects and Safety Concerns | -0.3% | Global, heightened in regulated markets | Short term (≤ 2 years) |
| Source: Mordor Intelligence | |||
Competition from conventional pharmaceutical products
Healthcare providers and consumers prefer drug therapies over nutritional interventions for managing cardiovascular risks. Medical professionals choose proven cardiovascular medications with clear dosing protocols, especially for high-risk patients who need immediate treatment. Bayer's KERENDIA (finerenone), approved by the FDA in 2025 for heart failure treatment, reduced cardiovascular death and heart failure events by 16%, showing how pharmaceuticals compete with nutritional approaches. Insurance companies cover pharmaceutical treatments more readily than nutritional supplements, which creates cost barriers for consumers interested in heart health ingredients. Drugs must undergo extensive Phase III trials, while supplements need only observational studies and smaller clinical trials. However, increasing focus on preventive healthcare and high cardiovascular treatment costs creates opportunities for heart health ingredients to serve as complementary therapies rather than primary treatments.
Stringent regulatory requirements for ingredient approval and health claims
Regulatory complexity affects market entry and innovation as manufacturers must comply with evolving approval processes and health claim requirements across global markets. The European Food Safety Authority's (EFSA) updated guidance for novel food applications, effective February 2025, implements stricter requirements for microorganism-related foods, production processes, and toxicological assessments. The Food and Drug Administration (FDA) has increased scrutiny of heart health supplements, issuing warning letters to companies making unauthorized disease claims about cholesterol and blood pressure management. EFSA's evaluation of red yeast rice monacolins exemplifies ongoing safety assessments that affect ingredient availability and market access. Small manufacturers face higher compliance costs, which create barriers to innovation and market entry while benefiting established companies with regulatory expertise. The differences in regulatory standards between regions affect global product development and marketing strategies, necessitating region-specific formulations and claims documentation.
Segment Analysis
By Type: Omega-3 Dominance Drives Innovation
Omega-3 fatty acids hold a dominant 36.14% market share in 2024, supported by strong consumer awareness and extensive clinical research validating their cardiovascular benefits. Coenzyme Q10 shows the highest growth potential with a projected CAGR of 6.98% through 2030, supported by research in heart failure treatment and cellular energy production. Beta-glucan maintains consistent market growth, supported by Food and Drug Administration (FDA) approved health claims for LDL cholesterol reduction [3]Source: Food and Drug Administration (FDA), "Health Claim Notification for Saturated Fat, Cholesterol, and Trans Fat, and Reduced Risk of Heart Disease", www.fda.gov. Phytosterols benefit from regulatory support, with approved coronary heart disease risk reduction claims in the United States and European Union.
Protein ingredients, including plant and dairy sources, show increasing demand among older consumers for their dual benefits in muscle maintenance and cardiovascular health. Technological developments in bioavailability enhancement and delivery systems are improving product effectiveness and user compliance. For instance, in October 2024, DSM-Firmenich launched Life's DHA B54-0100, an omega-3 formulation containing 545 mg of DHA per gram, enabling reduced capsule sizes to address consumption challenges in omega-3 supplementation.
Note: Segment shares of all individual segments available upon report purchase
By Source: Plant-Based Leadership Meets Algae Innovation
Plant-based sources hold a 56.55% market share in 2024, as consumers increasingly prefer sustainable and familiar ingredient origins. Algae-based alternatives show significant growth potential with a projected 7.15% CAGR through 2030. Animal-based sources experience declining preference due to sustainability concerns and dietary restrictions, though they remain important for applications requiring specific bioavailability profiles. Marine-derived ingredients show varied performance, with traditional fish oil facing sustainability challenges while algae cultivation emerges as an environmentally sustainable alternative.
The transition to algae-based sources marks a significant change in omega-3 production, addressing sustainability and quality requirements. Schizochytrium cultivation produces high DHA concentrations in controlled environments, eliminating risks of marine biotoxins and heavy metal contamination. Plant-based ingredient development continues to expand, with Tiger nut oil receiving European Food Safety Authority (EFSA) approval for its oleic acid content and cardiovascular benefits.
By Form: Powder Convenience Versus Liquid Bioavailability
Powder formulations dominate the global heart health ingredients market, holding a 61.12% market share in 2024. This dominance stems from their manufacturing efficiency, extended shelf stability, and consumer acceptance across functional foods and supplements. Powders provide versatility in product development, enabling integration into beverages, meal replacements, and sachet-based supplements. The advancement of technologies like liquisolid systems addresses solubility challenges for fat-soluble heart health compounds, including Coenzyme Q10 and omega-3 fatty acids. These systems convert poorly soluble liquids into dry, free-flowing powders, improving dissolution rates and therapeutic efficacy for enhanced bioavailability and consistent cardiovascular benefits.
Liquid formulations represent the fastest-growing segment, with a projected CAGR of 7.56% through 2030. This growth reflects increasing demand for fast-acting, easily absorbed formats, particularly among seniors and health-conscious consumers seeking immediate benefits from heart-healthy ingredients such as omega-3s and botanical extracts. Liquids offer enhanced bioavailability and faster onset of action, making them suitable for functional beverages, emulsions, and concentrated shots.
Note: Segment shares of all individual segments available upon report purchase
By Application: Supplements Lead While Functional Foods Accelerate
Dietary supplements dominate the global heart health ingredients market with a 51.25% market share in 2024. This leadership position stems from established consumer purchasing patterns and clinical marketing efforts over decades. The segment's success is attributed to clear labeling, precise dosing, and extended shelf-life, making it particularly appealing to older adults and individuals managing conditions like high cholesterol or hypertension. The regulatory environment in numerous countries supports this dominance by allowing structure/function claims for cardiovascular wellness without requiring pharmaceutical-level approvals. These factors establish supplements as the market's foundation, characterized by strong consumer loyalty and accessible product development opportunities.
Functional foods and beverages demonstrate significant growth potential, with a projected CAGR of 6.87% through 2030. Manufacturers are integrating heart health ingredients into common food items, including fortified cereals, dairy products, juices, and snack bars. This integration reflects the growing consumer preference for incorporating health management into daily nutrition. The pharmaceutical segment maintains steady growth through prescription and over-the-counter (OTC) formulations for heart failure, hypertension, and hyperlipidemia. These medical applications utilize ingredients such as CoQ10, niacin, and EPA/DHA, adhering to stringent quality and efficacy standards.
Geography Analysis
North America holds 38.46% market share in 2024, supported by clear regulations, robust healthcare systems, and high public awareness of cardiovascular health risks. Companies like Cargill and Archer Daniels Midland Company utilize the region's manufacturing capabilities and regulatory expertise for global distribution. However, market maturity and increased regulatory oversight limit growth opportunities beyond traditional supplement markets.
Asia-Pacific registers the highest growth rate at 7.21% CAGR through 2030, driven by increasing cardiovascular disease incidence and growing middle-class healthcare expenditure. Regional health challenges, including air pollution, changing dietary patterns, and high hypertension rates, increase ingredient demand across multiple applications. The region expands manufacturing capacity through strategic partnerships, while regulatory alignment efforts improve market access for global suppliers.
Europe maintains consistent growth, supported by strict regulations that boost consumer trust in heart health ingredients while restricting unproven products. The region's aging population and comprehensive healthcare systems promote preventive nutrition adoption, especially in Nordic countries with developed functional food markets. Post-Brexit regulatory differences require manufacturers to comply with separate European Union and United Kingdom frameworks. Additionally, the European Union Deforestation Regulation (EUDR) influences ingredient sourcing practices across the food and supplement sectors.
Competitive Landscape
The food ingredients market displays moderate fragmentation, with established suppliers holding market leadership through integrated operations, regulatory compliance, and technological advancement. Key companies, including Cargill Incorporated, DSM-Firmenich AG, Archer Daniels Midland Company, BASF, and Kerry Group, maintain their competitive position through global manufacturing networks and research investments. Industry consolidation continues, as demonstrated by Tate & Lyle's USD 1.8 billion acquisition of CP Kelco in November 2024, strengthening its position in specialty food solutions and natural ingredients portfolios.
Companies focus on technology-driven differentiation through investments in artificial intelligence for nutrition solutions, delivery systems, and sustainable production methods. The market participants prioritize bioavailability enhancement, sustainable sourcing practices, and application-specific formulations to meet consumer preferences and regulatory requirements. Significant market opportunities exist in personalized nutrition platforms, algae-based ingredient production, and expansion into emerging markets with developing regulatory frameworks.
Specialized companies target niche market segments through innovative extraction methods, new ingredient sources, and focused application development. These organizations face challenges in scaling production capabilities and managing regulatory compliance across global markets. The competitive environment continues to evolve as companies adapt to regulatory changes and market demands while maintaining operational efficiency and product development initiatives.
Heart Health Ingredients Industry Leaders
-
Cargill, Incorporated
-
DSM-Firmenich AG
-
Archer Daniels Midland Company
-
BASF SE
-
Kerry Group plc
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- February 2025: Layn Natural Ingredients introduced a new beta glucan ingredient and expanded its biotechnology facility. The ingredient's high water solubility enables its use across multiple applications.
- December 2024: ACI Group introduced Hytolive and Vintera, products containing hydroxytyrosol, an antioxidant that helps reduce cholesterol levels and supports cardiovascular health.
- May 2024: Ohly introduced its NEIVA health product line, focusing on heart health and immunity support. The initial products in the portfolio, NEIVA Glucan Max and NEIVA MCT Immune, contain yeast beta-glucans and offer benefits for immune function, cardiovascular health, and general wellbeing.
- May 2023: Corbion entered the human nutrition industry by launching its AlgaVia product line. The portfolio includes products rich in omega-3s and omega-9s, which provide the concentrations required to support brain health, immune function, eye health, and heart health in humans.
Global Heart Health Ingredients Market Report Scope
The global heart health market is segmented into product type, distribution channels, and geography. By product type, it is divided into Omega 3 fatty acids, beta-glucan, phytosterol, soy protein, and others. By distribution channel, it is segmented into supermarket/hypermarket, specialist stores, drug stores, online retail, and others. By geography, it is segmented into North America, Europe, Middle-East and Africa, South America, and Asia-Pacific. The report offers the market size and forecasts for the heart health ingredient market in value (USD million) for all the above segments.
| Omega-3 Fatty Acids |
| Beta-Glucan |
| Phytosterols |
| Protein |
| Coenzyme Q10 |
| Others |
| Plant-based |
| Animal-based |
| Algae-based |
| Others |
| Powder |
| Liquid |
| Others |
| Dietary Supplements |
| Functional Food and Beverage |
| Pharmaceuticals |
| Others |
| North America | United States |
| Canada | |
| Mexico | |
| Rest of North America | |
| Europe | Germany |
| United Kingdom | |
| Italy | |
| France | |
| Spain | |
| Netherlands | |
| Poland | |
| Belgium | |
| Sweden | |
| Rest of Europe | |
| Asia-Pacific | China |
| India | |
| Japan | |
| Australia | |
| Indonesia | |
| South Korea | |
| Thailand | |
| Singapore | |
| Rest of Asia-Pacific | |
| South America | Brazil |
| Argentina | |
| Colombia | |
| Chile | |
| Peru | |
| Rest of South America | |
| Middle East and Africa | South Africa |
| Saudi Arabia | |
| United Arab Emirates | |
| Nigeria | |
| Egypt | |
| Morocco | |
| Turkey | |
| Rest of Middle East and Africa |
| By Type | Omega-3 Fatty Acids | |
| Beta-Glucan | ||
| Phytosterols | ||
| Protein | ||
| Coenzyme Q10 | ||
| Others | ||
| By Source | Plant-based | |
| Animal-based | ||
| Algae-based | ||
| Others | ||
| Form | Powder | |
| Liquid | ||
| Others | ||
| By Application | Dietary Supplements | |
| Functional Food and Beverage | ||
| Pharmaceuticals | ||
| Others | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Rest of North America | ||
| Europe | Germany | |
| United Kingdom | ||
| Italy | ||
| France | ||
| Spain | ||
| Netherlands | ||
| Poland | ||
| Belgium | ||
| Sweden | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| India | ||
| Japan | ||
| Australia | ||
| Indonesia | ||
| South Korea | ||
| Thailand | ||
| Singapore | ||
| Rest of Asia-Pacific | ||
| South America | Brazil | |
| Argentina | ||
| Colombia | ||
| Chile | ||
| Peru | ||
| Rest of South America | ||
| Middle East and Africa | South Africa | |
| Saudi Arabia | ||
| United Arab Emirates | ||
| Nigeria | ||
| Egypt | ||
| Morocco | ||
| Turkey | ||
| Rest of Middle East and Africa | ||
Key Questions Answered in the Report
What is the current valuation of the heart health ingredients market?
The market is worth USD 9.41 billion in 2025 and is projected to reach USD 12.47 billion by 2030, expanding at a 5.80% CAGR.
Which ingredient type leads the heart health ingredients market?
Omega-3 fatty acids lead with 36.14% market share in 2024 owing to extensive clinical evidence and strong consumer trust.
Which region is the fastest growing for heart health ingredients?
Asia-Pacific is forecast to grow at a 7.21% CAGR through 2030, driven by escalating cardiovascular disease prevalence and rising disposable income.
Why are algae-based omega-3 sources gaining popularity?
Algae cultivation offers high DHA purity, avoids marine contaminants, and aligns with sustainability goals, driving a 7.15% CAGR for algae-sourced ingredients.
Page last updated on: